Ultimovacs Q1 2022: Patient recruitment is progressing well - Redeye

Redeye comments on Ultimovacs’ Q1 report; with patient recruitment for the company’s phase II trials progressing steadily, we judge. We believe the company sits on a comfortable cash cushion, providing ample funding runway through several potential major value inflection points.

Länk till analysen i sin helhet: https://www.redeye.se/research/841804/ultimovacs-q1-2022-patient-recruitment-is-progressing-well?utm_source=finwire&utm_medium=RSS